CoChat

Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium

M. Neyt, C. De Laet, H. Van Brabandt, O. Franco, D. Ramaekers · 2009 · Acta Cardiologica

The DOI matches its Crossref record.

Abstract

OBJECTIVES: 8% of total drug spending by the Belgian government goes to statins. The aim of this study is to determine the cost-effectiveness of statins for the primary prevention of cardiovascular disease (CVD) in middle-aged Belgian populations. METHODS AND RESULTS: Economic evaluations were identified in a systematic literature search and were critically appraised. Furthermore, because prices decreased drastically, a previously published model was adapted applying recent cost data from the Belgian national health insurance. Eleven full economic evaluations were identified. Nine studies compared statins with no treatment and presented heterogeneous results. If alternative interventions, such as smoking cessation or low-dose aspirin treatment were included in the analysis, statin therapy became less cost-effective. Prescribing the cheapest statin on the Belgian market (< Euro 90 medication cost per year) resulted in an incremental cost of Euro 29,173 per life-year gained (LYG) in a male high-risk group aged 60 compared to low-dose aspirin. The incremental cost in a male moderate-risk group aged 50 was Euro 87,022/LYG. Low-dose aspirin was more cost-effective ranging from Euro 3,854/LYG to Euro 29,509/LYG compared to smoking cessation therapy. Smoking cessation therapy was the most cost-effective intervention, providing savings compared to no treatment. CONCLUSIONS: In Belgium, the cost-effectiveness of statins for the primary prevention of CVD is rather elevated in comparison with low-dose aspirin, even if the cheapest statin is prescribed. From an economic point of view, prevention with low-dose aspirin is more cost-effective and may present a first choice in primary prevention. Smoking cessation, which is a dominant strategy, should be encouraged at all times.

Overview

Integrity signals

Registry

Crossref · 10.2143/ac.64.1.2034354

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 19

Metadata

Authors
Neyt, M., Laet, C. D., Brabandt, H. V., Franco, O., & Ramaekers, D.
Affiliations
Belgian Health Care Knowledge Centre (KCE) (BE)
Venue
Acta Cardiologica
Published
2009-02-28
Volume
64
Issue
1
Pages
1-10
ISSN
0001-5385 (ISSN-L)
OpenAlex
W2002405282
Cited by
15
References
0
Citations by year
2016: 3 · 2015: 3 · 2014: 1
FWCI
2.70
Type
journal article
Language
en
Open access
closed
Locations
  • Acta Cardiologica (publishedVersion)
  • PubMed (publishedVersion)
  • KCE repository (Belgian Health Care Knowledge Centre) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
statins, cost-effectiveness, primary prevention, cardiovascular disease, low-dose aspirin, smoking cessation, middle-aged adults, drug spending, life-years gained, economic evaluation
MeSH terms
Aspirin, Belgium, Cardiovascular Diseases, Cost-Benefit Analysis, Health Policy, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Smoking Cessation, Risk Assessment, Models, Economic, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. https://app.cochat.ai/papers/10.2143/ac.64.1.2034354
The paper
Neyt, M., Laet, C. D., Brabandt, H. V., Franco, O., & Ramaekers, D. (2009). Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiologica. https://doi.org/10.2143/ac.64.1.2034354

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.